

November 9, 2015

Dear Manufacturers,

I am writing on behalf of Lincoln Medical and Mental Health Center, (Lincoln), 340B ID DSH330088, to inform manufacturers that Lincoln recently underwent an audit by the Health Resources and Services Administration (HRSA) of Lincoln's compliance with 340B Drug Pricing Program (340B) requirements.

As background, Lincoln qualified for the 340B Program as a Disproportionate Share Hospital at 234 149th Street, Bronx, New York 10451, and has participated in the 340B Program since December 1, 1992.

Through the audit process, Lincoln was found to have non-compliance within their 340B Program and is responsible for repayment as a result of the following findings:

- 1) Lincoln obtained covered outpatient drugs through a GPO

Lincoln was purchasing ten (10) covered outpatient controlled substance pharmaceuticals through a GPO account; a small percentage were used in mixed-use areas. Since February 3, 2014, these controlled substances have been purchased through a wholesale acquisition account.

- 2) Lincoln dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B)

The transactions of the three prescriptions incorrectly deemed 340B-eligible were reversed, and two prescribing physicians were removed from Lincoln's 340B eligible provider data base.

Lincoln has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from Lincoln and believe repayment may be owed for the violation described in this letter, or if you have any questions or comments regarding the violation described in this letter, within the next 90 days from the date of this letter, please contact Mr. Paul A. Albertson, Sr. Assistant Vice President, Supply Chain Services, New York City Health and Hospitals Corporation, 160 Water Street, 13th Floor, New York, NY 10038, telephone number 212-748-2256, email: paul.albertson@nychhc.org

Sincerely yours,

Antonio D. Martin